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The epidermal growth factor receptor (EGFR) is
implicated in human cancers and is the target of
several classes of therapeutic agents, including anti-
body-based drugs. Here, we describe X-ray crystal
structures of the extracellular region of EGFR in
complex with three inhibitory nanobodies, the vari-
able domains of heavy chain only antibodies (VHH).
VHH domains, the smallest natural antigen-binding
modules, are readily engineered for diagnostic and
therapeutic applications. All three VHH domains pre-
vent ligand-induced EGFR activation, but use two
distinct mechanisms. 7D12 sterically blocks ligand
binding to EGFR in a manner similar to that of cetux-
imab. EgA1 and 9G8 bind an epitope near the EGFR
domain II/III junction, preventing receptor confor-
mational changes required for high-affinity ligand
binding and dimerization. This epitope is accessible
to the convex VHH paratope but inaccessible to
the flatter paratope of monoclonal antibodies.
Appreciating the modes of binding and inhibition of
these VHH domains will aid in developing them for
tumor imaging and/or cancer therapy.
INTRODUCTION
Aberrant activation of the epidermal growth factor receptor
(EGFR) is implicated in a number of human cancers, including
colorectal, lung, brain, and head and neck tumors (Baselga
and Arteaga, 2005; Gullick, 1991; Huang et al., 2009). It is well
established that antibody binding to the extracellular region of
EGFR can inhibit ligand-induced receptor activation and tumor
growth (Gill et al., 1984; Sato et al., 1983). Several antibodies
with these properties, including cetuximab/Erbitux, are in current
use or development in the clinic (Schmitz and Ferguson, 2009;
You and Chen, 2012; Zhang et al., 2007).
Whereas antibodies that bind EGFR and other targets have
shown promise in the clinic, there are impediments to their effec-
tive application and future development (Beck et al., 2010). The
large size of monoclonal antibodies (mAbs) limits their ability to1214 Structure 21, 1214–1224, July 2, 2013 ª2013 Elsevier Ltd All rigpenetrate tumors, restricting their effectiveness, and generation
of new or modified mAbs is costly and laborious. Both problems
can be mitigated by exploiting heavy-chain-only antibodies
(HCAbs) from camelids (Hamers-Casterman et al., 1993; Muyl-
dermans et al., 1994). Whereas the antigen-recognition region
in conventional antibodies comprises the variable regions of
both heavy and light chains (VH and VL, respectively), the anti-
gen-recognition region of HCAbs comprises a single variable
domain, referred to as domain or nanobody. This single Ig
domain is stable and can be generated rapidly and cheaply
with simple expression systems (Harmsen and De Haard,
2007). Single VHH domains can be powerful diagnostic imaging
tools, and they are being developed for a range of research
applications (Steyaert and Kobilka, 2011; Vaneycken et al.,
2011). For therapeutic use, VHH domains (monomeric or
multivalent) can be modified to extend serum half-life and/or
functionality (Saerens et al., 2008).
The clinical success of EGFR-targeted mAbs has prompted
significant interest in developing VHH domains that bind to and
inhibit this receptor. Several EGFR-specific VHH domains have
been reported (Roovers et al., 2007, 2011) that have the potential
to reproduce the clinical efficacy of mAbs such as cetuximab in
an agent that is more stable and far less costly to produce. More-
over, potent multivalent VHH molecules can be generated that
bind a number of targets (Emmerson et al., 2011; Ja¨hnichen
et al., 2010; Roovers et al., 2011), offering the potential to engi-
neer multivalent agents that combine cetuximab-like EGFR inhi-
bition with other modes of binding to EGFR or to other cancer
targets. Fusing the targeted VHH domain (or domains) to one
that recognizes serum albumin can also dramatically increase
serum half-life (Tijink et al., 2008).
We previously described the structural basis of EGFR inhibi-
tion by Fab fragments from three different mAbs, cetuximab,
necitumumab, and matuzumab (Li et al., 2005, 2008; Schmiedel
et al., 2008). Each mAb sterically blocks a large conformational
transition from an unactivated or ‘‘tethered’’ extracellular EGFR
configuration to one that is dimerization-competent. In the
tethered configuration, two of the four domains in the EGFR
extracellular region (domains II and IV) make intramolecular
autoinhibitory contacts, occluding the dimerization interface
and separating the two halves of the EGF binding site (in
domains I and III). Ligand binding stabilizes a conformation in
which domains I and III are brought close together and domain
II/IV intramolecular interactions are broken (Burgess et al.,hts reserved
Table 1. Equilibrium Binding Constants of sEGFR Binding to
Inhibitory VHH Domains
Immobilized
VHH
KD Value (nM) for Binding of Indicated Analyte
sEGFR sEGFR501 sEGFRd3 sEGFRvIII
7D12 219 ± 20 (279 ± 19) 143 ± 18 47 ± 3.6 263 ± 33
EgA1 276 ± 7.0 (238 ± 42) 356 ± 19 >2,500 822 ± 57
9G8 166 ± 1.2 (263 ± 76) 317 ± 14 >5,000 525 ± 51
Numbers in parentheses are KD values for binding to exogenously bio-
tinylated VHH immobilized on streptavidin-coated SA sensor chips. All
other KD values were determined for binding to VHH-AVIs that were
amine coupled to CM5 sensor chips.
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Structural Basis of VHH Domain EGFR Inhibition2003). All three EGFR-targeted mAbs bind to domain III (Schmitz
and Ferguson, 2009). The epitopes of cetuximab and necitumu-
mab overlap with the domain III ligand-binding region, whereas
the matuzumab epitope does not. Cetuximab and necitumumab
inhibit EGFR by directly interfering with ligand binding and block-
ing the activating conformational transition (Li et al., 2005, 2008).
Matuzumab inhibits EGFR exclusively by preventing the acti-
vating conformational transition (Schmiedel et al., 2008).
In this report, we describe the structural basis for EGFR inhibi-
tion by three VHH domains. In multivalent formats, each of these
VHH domains block ligand-induced EGFR activation and cellular
proliferation (Roovers et al., 2007, 2011). Our structural analysis
reveals modes of conformational constraint of EGFR by these
VHH domains that have not been seen with inhibitory mAbs.
The three VHH domains were isolated from an ‘‘immune’’ phage
library generated from lymphocytes of Llama glama that had
been immunized with A431 epidermoid carcinoma cells and
A431 membrane preparations (Gainkam et al., 2008; Hofman
et al., 2008; Roovers et al., 2007). One VHH domain (7D12)
was selected for its ability to compete with cetuximab for
EGFR binding (Roovers et al., 2011). We show how the much
smaller VHH domain can block both cetuximab and ligand bind-
ing. The other two VHH domains (EgA1 and 9G8) arose from a
screen for molecules that inhibit ligand binding to EGFR (Hofman
et al., 2008; Roovers et al., 2007)—the same strategy used to
select the originator of cetuximab from a panel of mouse mono-
clonal antibodies (Sato et al., 1983). Interestingly, EgA1 and 9G8
do not compete with cetuximab for binding to EGFR (Roovers
et al., 2011). Instead, these VHH domains bind to an epitope
that is inaccessible to cetuximab and that undergoes large
conformational changes during EGFR activation—sterically in-
hibiting the receptor.
RESULTS
VHH Domain Binding to the EGFR Extracellular Region
We first determined the affinity constants for interaction of each
VHH domain with the EGFR extracellular region using surface
plasmon resonance (SPR). Soluble EGFR extracellular region
(sEGFR; amino acids 1–618 of the mature protein; Ferguson
et al., 2000) was passed over sensor chips on which VHH
domains 7D12, EgA1, or 9G8 had been immobilized by amine
coupling. The equilibrium SPR response was measured over a
range of sEGFR concentrations, and the resulting data were fit
to a single-site Langmuir binding equation. To evaluate possible
bias due to covalent immobilization of VHH domains on theStructure 21, 1sensor surface, we also conducted binding assays in which
biotinylated VHH domains were bound to streptavidin-coated
sensor chips. Similar binding constants were determined by
both methods (Table 1).
The dissociation constant (KD) values for binding of sEGFR
to immobilized VHH domains were between 166 and 276 nM
(Table 1). These affinities are 50- to 100-fold weaker than those
for sEGFR binding to the structurally characterized Fab frag-
ments of cetuximab (2.3 ± 0.5 nM) (Li et al., 2005) and necitumu-
mab (3.3 ± 0.5 nM) (Li et al., 2008), but are similar to those
reported for the matuzumab Fab fragment (113 ± 25 nM)
(Schmiedel et al., 2008). The apparent KD value for the binding
of 7D12 to cell-surface EGFR has been reported in the low nano-
molar range (Oliveira et al., 2012), suggesting that additional fac-
tors that are only manifest at the cell surface may contribute to
binding of this VHH to EGFR. Similar observations were made
for matuzumab (Schmiedel et al., 2008).
As an initial approach for assigning epitopes to domains in
sEGFR, we measured VHH domain binding to sEGFR truncation
variants. Deleting most of domain IV (with sEGFR501) has little
effect on binding (<2-fold) for all three VHH domains (Table 1).
Studies with isolated domain III (sEGFRd3; amino acids 311–
514) revealed a complete loss of EgA1 and 9G8binding, whereas
7D12 bindingwas retained—and increased approximately 4-fold
(suggesting that its epitope lies entirely on domain III). Interest-
ingly, all three VHH domains bound to the truncated extracellular
region of the oncogenic EGFR variant III (sEGFRvIII), which lacks
domain I and much of domain II, but retains residues 273–311 of
domain II (Sugawa et al., 1990; Wong et al., 1992). The fact that
EgA1 and 9G8 bind sEGFRvIII but not sEGFRd3 suggests that
significant parts of their epitopes may lie in the C-terminal part
of domain II.
Antibody Cross-Competition
To compare the location of the epitopes for the three VHH
domains with those of cetuximab and mAb425 (the murine
version of matuzumab) and the EGF binding site, we used
SPR-based competition assays. Fab fragments from cetuximab
(Fab225) and mAb425 (Fab425), and EGF, were amine coupled
to CM5 sensor chips. The equilibrium SPR responses obtained
for injections of 100 nM sEGFR with and without 5 mM of each
VHH were measured (Figure 1A). All three VHH domains dramat-
ically reduced EGF binding by sEGFR, which could arise through
direct competition for the ligand-binding site and/or indirect
conformational effects. VHH 7D12 reduces the SPR response
to a level similar to that observed for competition with cetuximab,
as expected, whereas EgA1 and 9G8 compete more effectively
than mAb425 for sEGFR binding to EGF. Only 7D12 reduces
sEGFR binding to FabC225, suggesting that its binding site on
domain III may overlap with the cetuximab epitope. VHH do-
mains 9G8 and EgA1 both abolished sEGFR binding to immobi-
lized Fab425. Addition of 9G8 and EgA1 to sEGFR enhanced the
SPR response for immobilized FabC225, suggesting that these
VHH:sEGFR complexes can bind to FabC225. These data
confirm and extend our previous results using phage-displayed
versions of these VHH domains to compete with mAbs for bind-
ing to an immobilized Fc fusion of sEGFR (Roovers et al., 2011).
To further investigate the simultaneous binding of EgA1 and
FabC225 to sEGFR, we used sedimentation-velocity analytical214–1224, July 2, 2013 ª2013 Elsevier Ltd All rights reserved 1215
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Figure 1. Cross-Competition of VHH, Fab, and EGF Binding to sEGFR
(A) BIAcore analysis of the effect of added competitor upon binding of sEGFR to immobilized EGF or Fab. For CM5 sensor chips to which EGF, FabC225, or
Fab425 had been amine coupled, the SPR responses for 100 nM sEGFR plus 5 mMVHH (7D12, EgA1, or 9G8) or 10 mMmAb (cetuximab or mAb425) are shown,
normalized to the SPR response for 100 nM sEGFR alone. Error bars indicate the standard deviation of at least three independent measurements.
(B) Sample of 5 mMsEGFR alone andmixtures of 5 mMsEGFRwith (1) 5 mMEgA1, (2) 5 mMFabC225, or (3) 5 mMEgA1 plus 5 mMFabC225 were subject to velocity
ultracentrifugation. Sedimentation velocity c(S) species analysis shows that sEGFR forms 1:1 complexes with EgA1 (5.4S) and FabC225 (6.2S), and a ternary
EgA1:FabC225:sEGFR (6.6S) when VHH and Fab are added.
(C) Similar velocity centrifugation shows a ternary 2xVHH:sEGFR complex (5.9S) for mixtures of sEGFR with EgA1 and 7D12, whereas only 1:1 VHH:sEGFR
complex (5.4S) is seen for samples containing sEGFR, EgA1, and 9G8.
See also Figure S1.
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Structural Basis of VHH Domain EGFR Inhibitionultracentrifugation (SV-AUC). Whereas sEGFR alone (at 5 mM)
sediments at 4.8 S, adding 5 mM EgA1 or 5 mM FabC225 yields
species that sediment at 5.4S (EgA1:sEGFR) or 6.2S (FabC225:
sEGFR), respectively (Figure 1B)—consistent with the forma-
tion of 1:1 complexes. When both EgA1 and FabC225 are
added, a larger species (6.6S) consistent with a trimolecular
complex is seen. By contrast, binding of FabC225 and 7D12
are mutually exclusive (not shown). Similar experiments reveal
that 7D12 and EgA1 can both bind to the same sEGFR mole-
cule to form a ternary EgA1:7D12:sEGFR complex of 5.9S
(Figure 1C). When EgA1 and 7D12 are linked with a 10-amino-
acid glycine/serine linker (7D12-EgA1), formation of a 1:2
7D12-EgA1:sEGFR complex of 8.3S is favored (Figure S1
available online). This suggests that the increased potency of
a 7D12-EgA1-like biparatopic inhibitor CONAN-1 (Roovers
et al., 2011) is not due to the simultaneous binding of both
VHH modules of the biparatopic inhibitor to a single EGFR
molecule.
The VHH 7D12 Epitope on Domain III
To visualize the molecular details of 7D12 binding to EGFR, we
determined the crystal structure of 7D12 bound to sEGFRd3.
The 7D12:sEGFRd3 complex crystallized in two distinct condi-
tions: crystals grown at pH 6.0 diffracted to 2.9 A˚ resolution,
and those grown at pH 3.5 diffracted to 2.7 A˚ resolution (Table 2).
Both structures were solved using molecular replacement
(MR) in PHASER (McCoy et al., 2007), using sEGFRd3 (Protein
Data Bank [PDB] ID 3B2U) and the framework region of VHH
EgA1 (see below) as search models. Models were rebuilt in
Coot (Emsley and Cowtan, 2004) and refined using REFMAC
(CCP4, 1994), CNS (Bru¨nger et al., 1998), and PHENIX (Adams
et al., 2010). The structures from the two crystal forms superim-
pose with a root-mean-square deviation (rmsd) of <1.0 A˚, and1216 Structure 21, 1214–1224, July 2, 2013 ª2013 Elsevier Ltd All rigthe contacts stabilizing the interaction are identical in the two
structures.
The framework region of 7D12 has a typical VH Ig fold, aligning
to the framework region of VHH cAb-Lys3 (Desmyter et al., 1996)
with an rmsd of 0.52 A˚. The sEGFRd3 aligns with previously re-
ported crystal structures of this domain (Ferguson et al., 2003;
Garrett et al., 2002; Li et al., 2005, 2008; Ogiso et al., 2002;
Schmiedel et al., 2008) with an rmsd of <1.0 A˚. 7D12 binds to
a flat surface on domain III (Figure 2) that corresponds to the
location of the epitope for cetuximab and of the domain III
ligand-binding site (Figure 3). As shown in Figure 2C, VHH
complementarity-determing region 1 (CDR1) and CDR3 contact
the first two turns of the domain III b-helix (amino acids 310–375);
CDR2 makes no contacts with sEGFR. The complex buries
about 700 A˚2 on each protein, 48% of which is hydrophobic in
nature. The interface has a shape complementarity parameter
(Lawrence and Colman, 1993) of 0.68, which is typical for anti-
body/antigen interfaces (Table S1).
A cluster of polar and electrostatic interactions occurs in the
center of the 7D12 epitope (Figure 2C). An arginine on CDR1
(R30) makes a salt bridge to EGFR D355 (a critical side chain
in EGF binding), and two acidic side chains (D101 and E100f)
plus main-chain carbonyls from CDR3 engage the side chains
of R353 and Q384 on EGFR. These central polar interactions
are flanked by apolar contacts. On one side, the aliphatic portion
of 7D12 R30 packs against EGFR F357, and on the other side,
Y100e from CDR3 packs against an N-acetylglucosamine
(GlcNAc) linked to EGFR N420 that is rotatedz90 with respect
to its typical position in EGFR domain III (Ferguson et al., 2003; Li
et al., 2005; Ogiso et al., 2002) to contribute to this interaction.
In line with the observed importance of electrostatic interac-
tions in the association of 7D12 with sEGFR, substitution of
7D12 R30 with alanine abolishes the interaction with sEGFR,hts reserved
Table 2. Crystallographic Statistics
Data Collection Statisticsa EgA1 7D12:sEGFRd3 (pH 6.0) 7D12:sEGFRd3 (pH 3.5) EgA1:FabC225:sEGFR 9G8:FabC225:sEGFR
Space group P43 P6122 P212121 P21 P21
Cell dimensions a, b = 52.7 A˚, a, b = 148.0 A˚, a = 78.7 A˚, b = 147.2 A˚, a = 66.2 A˚, b = 96.3 A˚, a = 66.4 A˚, b = 95.8 A˚,
c = 62.5 A˚ c = 82.5 A˚ c = 254.8 A˚ c = 128.1 A˚, b = 100.7 c = 129.5 A˚, b = 99.9
X-ray source APS 23-ID-B APS 23-ID-B APS 23-ID-B CHESS F1 APS 23-ID-B
Wavelength (A˚) 0.980 1.033 0.980 0.918 0.980
Resolution limit (A˚) 1.55 2.85 2.65 3.05 2.80
Measured/Unique 107,430/24,694 136,787/22,976 568,198/83,116 69,621/29,807 138,909/37,840
Fold redundancy 4.4 6.0 6.8 2.3 1.9
Completeness (%) 99.2 (94.5) 97.0 (73.4) 96.6 (75.4) 98.8 (99.6) 99.0 (92.4)
Rsym
b 0.037 (0.283) 0.117 (0.574) 0.108 (0.614) 0.099 (0.463) 0.096 (0.413)
hI/si 47.5 (4.4) 21.9 (2.0) 20.7 (2.0) 10.7 (2.2) 14.8 (2.3)
Refinement Statistics
Resolution limits (A˚) 27–1.55 41.8–2.85 49.52–2.66 38.2–3.05 47.92–2.82
No. of reflections/
No. in test set
23,399/1,252 12,061/617 78,792/4,233 28,283/1,507 35,947/1,889
R factor (Rfree)
c 0.19 (0.21) 0.22 (0.27) 0.21 (0.24) 0.22 (0.28) 0.22 (0.26)
Model: VHH 1–73, 77–129 1–122 6 3 1–124d 1–7, 20–127 2–11, 20–124
sEGFR or sEGFRd3 – 307–511 6 3 307–503d 4–100, 108–183,
208–604
4–132, 208–612
FabC225 heavy chain – – – 1–135, 141–218 1–136, 141–218
FabC225 light chain – – – 1–211 1–211
Ions 1 sulfate ion 2 MES ions;
1 iodide ion,
– – –
Water molecules 84 36 170 12 3
Total number of atoms 1,074 2,527 14,923 7,952 7,866
Ramachandran: favored 96.9 96.3 96.4 91.4 92.1
Outliers (%) 0 0.3 0.2 0.2 0.1
Rmsd bond lengths (A˚) 0.007 0.005 0.005 0.006 0.006
Rmsd bond angles () 1.111 0.876 0.858 0.902 0.948
aNumbers in parentheses refer to last resolution shell.
bRsym = SjIh  hIhij/SIh, where hIhi = average intensity over symmetry equivalent measurements.
cR factor = SjFo  Fcj/SFo, where summation is over data used in the refinement; Rfree includes only 5% of the data excluded from the refinement.
dNumber of missing amino acids varies by chain.
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Structural Basis of VHH Domain EGFR Inhibitionand replacing D101with alanine weakens binding to the receptor
by 3-fold (Table 3).
Comparison of EGF, Cetuximab, and 7D12 Binding
The epitope for 7D12 partially overlaps both the ligand-binding
site and the cetuximab epitope on domain III (Figure 3). As pre-
viously described (Ogiso et al., 2002), EGF interactions with
domain III fall into two groups (circled in Figure 3B; sites 2 and
3 of Ogiso et al. 2002). Interactions of 7D12 with domain III are
primarily centered on site 2, mimicking (with R30 in CDR1) the
salt bridge with EGFR D355 (and van der Waals contact with
F357) made by R41 in EGF. 7D12 binding does not utilize the
hydrophobic pocket on the domain III surface that lies at the
center of site 3 (Figure 3B) into which L47 of EGF projects. By
contrast with the site 2 focus of 7D12, C225 binding is largely
centered on site 3 (Figure 3C)—and C225 does not engage site
2 on domain III (Li et al., 2005). The different foci of the interac-
tions of 7D12, EGF, and C225 are most apparent when
comparing the projection of the binding footprint of EGF withStructure 21, 1the 7D12 and cetuximab epitopes on domain III (Figure 3). The
EGF-binding site encompasses sites 2 and 3, whereas 7D12
engages site 2, and cetuximab only site 3. Consistent with the
structural observations, substitution of F357 and D355 in EGFR
(D355T/F357A) reduces 7D12 binding (Table 3) but not cetuxi-
mab binding (Li et al., 2005).
EgA1 and 9G8 Bind to an Epitope on Domain III Adjacent
to Domain II
We next sought to understand the structural basis of EGFR bind-
ing and inhibition by EgA1 and 9G8. Although EgA1 and sEGFR
stably associate in solution (Figure 1B), we were unable to crys-
tallize an EgA1:sEGFR complex. We were able to obtain crystals
of the EgA1:FabC225:sEGFR ternary complex observed in our
SV-AUC experiments in Figure 1B, which diffracted to 3.05 A˚
resolution (Table 2), using the Fab fragment to aid crystallization,
in common with many other studies (Koide, 2009). We exploited
the same strategy to crystallize a 9G8:FabC225:sEGFR ternary
complex. These crystals were of the same space group and214–1224, July 2, 2013 ª2013 Elsevier Ltd All rights reserved 1217
Figure 2. The 7D12 Binding Site on Domain III of sEGFR
(A) Cartoon is shown with 7D12 colored green and sEGFRd3 colored gray.
CDRs are highlighted in light green and labeled.
(B) In this view, the structure has been rotated 180 about a vertical axis
relative to (A). The expected locations of domains I, II, and IV of sEGFR are in
light blue, based on the structure of tethered sEGFR in PDB ID 1NQL (Ferguson
et al., 2003).
(C) View of the interface region between 7D12 and sEGFRd3 in a similar
orientation to (A). Side chains that participate in key interactions are shown as
sticks, as is the sugar group on sEGFRd3. Predicted salt-bridge (%4.5 A˚) or
hydrogen-bond (%3.5 A˚) interactions are indicated with dashed lines. Kabat
numbering is used.
See also Figure S2.
Table 3. Effects of Epitope and Paratope Alterations on the
Equilibrium Binding of sEGFR to Immobilized VHHs
Immobilized VHH
KD Value (nM)
sEGFR sEGFR (D355T/F357A)
7D12 219 ± 20 >5000
7D12 (R30A) >4,000 ND
7D12 (D101A) 656 ± 22 ND
EgA1 276 ± 7.0 342 ± 6.5
EgA1 (R27A) >4,000 ND
EgA1 (D101A) >3,500 ND
9G8 166 ± 1.2 303.5 ± 12
9G8 (E100iA) >2,500 ND
Kabat numbering is used for VHH residues. ND, not determined.
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Structural Basis of VHH Domain EGFR Inhibitiondiffracted to 2.8 A˚ resolution. Both structures were solved byMR
methods using the FabC225:sEGFR and free EgA1 structures as
search models. The two VHH:FabC225:sEGFR structures align
with an overall backbone rmsd of 0.54 A˚—revealing that EgA1
and 9G8 bind to the same region on sEGFR.
EgA1 and 9G8 (hereafter EgA1/9G8) bind to sEGFR in its teth-
ered conformation, and the bound FabC225 makes identical
contacts with EGFR domain III, as seen in the previously re-
ported FabC225:sEGFR complex structure (Li et al., 2005)
(rmsd z0.5 A˚). Crystal packing is mediated predominantly by
contacts between the Fab and domain III of sEGFR from symme-
try-related molecules, suggesting a mechanism by which
FabC225 promotes crystallization. FabC225 and sEGFR domain
III are well ordered, as are portions of domains II, domain IV, and
the VHH paratope region (Figure S3). However, EGFR domain I,
the N-terminal portion of domain II, and the distal portion of the
VHH are poorly resolved. Parts of these regions are absent or
present as backbone atoms only in the refined model, and dihe-1218 Structure 21, 1214–1224, July 2, 2013 ª2013 Elsevier Ltd All rigdral angles in domain I were restrained to those from PDB
ID 1YY9.
EgA1/9G8 bind sEGFR in the cleft formed between domains II
and III (Figure 4), consistent with their ability to bind sEGFRvIII
but not sEGFRd3 in the binding studies described above. Inter-
action with sEGFR buries an average surface area on the partner
of 701 A˚2 for EgA1 and 636 A˚2 for 9G8 (Table S1). In both cases,
approximately 100 A˚2 of surface area on the VHH is occluded
from solvent by domain II, and the rest is occluded by domain
III. As with 7D12, CDRs 1 and 3 of EgA1/9G8 contribute the
key interactions, which are all made with domain III. CDR2
does not participate in the interaction. The CDR1 sequence is
identical in EgA1 and 9G8 (Figure S2), and in each case, R27
and Y32 participate in a cluster of interactions involving E431
and backbone moieties in EGFR. CDR3 of EgA1 and 9G8 shares
key sequence features, including Y96 (at the beginning), D101,
and Y102 (at the end), which make similar interactions with
EGFR domain III in each complex (Figure 4B, C). Y102 in each
VHH domain engages E431 from EGFR—also engaged by
CDR1. D101 and Y96 contribute to a second cluster of polar
and electrostatic interactions with two arginines of EGFR
(R403 and R405) and E400. The remainder of CDR3 is quite
different for each VHH (Figure S2). In each case, a side chain
from the VHH (D100 in EgA1 and E100i in 9G8) augments a
network of salt bridges formed by charged side chains in
EGFR—R403 to E376 to R310. This network is observed in all
crystal structures of tethered sEGFR, but is disrupted in ligand-
bound structures due to reorientation of the domain II/III linker re-
gion that leads to displacement of the R310 side chain by >7 A˚.
The importance of R310 in sEGFR binding to EgA1/9G8 explains,
in part, the lack of binding of these VHH domains to sEGFRd3. In
this truncation variant, the first four amino acids of mature
sEGFR (LEEK) are fused to amino acid 311 of domain III. Not
only does sEGFRd3 lack the R310 of domain III, but the two
N-terminal glutamic acids that replace it may also disrupt the
largely electrostatic interaction. In support of the importance of
electrostatic contacts in the interaction of these VHH domains
with sEGFR, we find that alanine substitution of R27 or D101 in
EgA1 or of E100i in 9G8 reduces binding by >20-fold (Table 3).
No well-ordered interactions between the VHH and sEGFR
domain II proper are observed in either crystal structure. How-
ever, in each case, the central region of CDR3 (near Y100d
in EgA1 and N100b in 9G8) is close enough that direct orhts reserved
Figure 3. Comparison of the Interactions of
EGF, FabC225, and 7D12 with EGFR
(A) Cartoon of the 7D12:sEGFRd3 complex.
Orientation is similar to that in Figure 2B. At right,
the footprint (green) of 7D12 on the surface of
domain III of EGFR highlights all atoms within 4 A˚
of the bound 7D12. This view onto the flat domain
III binding surface is with the complex rotated 90
about a horizontal axis.
(B) The interaction of EGF with domain III. Domain
III from PDB ID 1IVOwas overlaid with domain III in
the 7D12 complex. Orientations are as in (A). The
two groups of interactions between EGF and
domain III (sites 2 and 3) as defined by Ogiso et al.
(2002) are circled. The footprint for EGF is in gray.
(C) The interaction of FabC225 with domain III.
Domain III from PDB ID 1YY9 was overlaid with
domain III in the 7D12 complex. The footprint for
FabC225 is in red.
See also Table S1.
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Structural Basis of VHH Domain EGFR Inhibitionwater-mediated hydrogen bonds and van der Waals contacts
may occur. Water-mediated contacts are common in antibody:
antigen interactions (Davies and Cohen, 1996) but are not well
resolvedat the resolutionof theVHH:FabC225:sEGFRstructures.
Conformations of Free and Bound EgA1
We also determined the X-ray crystal structure of EgA1 in the
absence of EGFR to a resolution of 1.55 A˚. The framework region
of EgA1 is essentially identical in the bound and free structures,
which superimpose with a backbone rmsd of <1.0 A˚. However,
differences are apparent in the paratope (Figure 5). In free
EgA1, the N-terminal region projects between CDRs 1 and 3,
such that the side chain of V2 lies in a hydrophobic crevice
also occupied by Y32 (Figure 5B). In the bound structure, the
N-terminal region is instead oriented away from the Ig core and
makes polar contacts with domain III (Figure 4B). The side chain
of Y32 also reorients in the bound structure to participate in inter-
actions with sEGFR. The N-terminal part of CDR1, which does
not participate in direct interactions with sEGFR, adopts a
slightly different conformation in the bound structure (backbone
rmsd of 1.98 A˚ with free VHH), and the orientations of the T28 and
F29 side chains switch direction such that in the bound structure
F29 is flipped in toward the core of the protein, compensating in
part for the reorientation of V2 and Y32 (Figure 5B). Less exten-
sive rearrangements occur in CDRs 2 and 3. Of note, however, is
a shift in the positions of two tyrosine side chains (Y100d and
Y56; Figure 5C), which in the bound VHH structure adopt orien-
tations that place them closer to domain II than they would be in
their unbound orientations.Structure 21, 1214–1224, July 2, 2013 ªConformation of sEGFR in the EgA1
and 9G8 Complex
EGFR domains I and III in the EgA1/9G8
complex adopt conformations identical
to those seen in all other crystal struc-
tures of sEGFR. The orientation and
conformation of the first four disulfide-
bonded modules of domain II of sEGFR
in the VHH:FabC225:sEGFR ternary
complex is also similar to that observedfor all unliganded ErbB receptors (Alvarado et al., 2009; Bouyain
et al., 2005; Liu et al., 2012) (Figure S4A). The same is true for the
last disulfide-bonded module (m8) of domain II and the domain
II/III linker region (Figure S4B). The intervening three disulfide-
bonded modules of domain II (m5–m7) are substantially altered
in position, as a result of changes in the orientation of one
module with respect to its neighboring module in the m5/m6,
m6/m7, and m7/m8 connections. As shown in Figure S4C, this
results in a bend in domain II that reorients domain I with respect
to domain III in the ternary VHH:FabC225:sEGFR complex. This
difference could be the result of steric effects of bound VHH, or
may simply reflect inherent flexibility in sEGFR.
Although it is clear that domains II and IV are in close proximity
in the EgA1 complex, the structure is too poorly ordered to deter-
mine whether specific domain II/IV contacts are maintained. The
crystallographic data for the 9G8 complex yield interpretable
electron density in the region of the EGFR domain II/IV tether
interaction and suggest that at least two of the four hydrogen
bonds between domains II and IV are maintained in this complex
(backbone carbonyl of Y251 to side chain of H566, and between
the side chains of Y246 and D563). Together, these observations
argue that the binding of EgA1 and 9G8 does not substantially
perturb the conformation of tethered sEGFR.
Comparison of EgA1, 9G8, and Matuzumab Binding
to EGFR
The EgA1 (Figure 6A) and 9G8 (Figure 6B) epitopes are essen-
tially identical. These VHH epitopes partly overlap that of the
inhibitory antibody matuzumab (Figure 6C) (Schmiedel et al.,2013 Elsevier Ltd All rights reserved 1219
Figure 4. EgA1 and 9G8 Have Highly Divergent CDR3s but Bind to
Almost Identical Epitopes on sEGFR
(A) Overview of the EgA1:FabC225:sEGFR complex showing a cartoon plus
transparent molecular surface. The sEGFR is in gray, FabC225 is orange
(heavy chain) and yellow (light chain), and EgA1 is blue. At right is a close-up
view rotated 90 about a vertical axis, in which the location of EgA1 in a cleft
between domains II and III can be appreciated. In this view, a solid surface has
been rendered on sEGFR and domains I and II are colored light blue for
contrast.
(B) Close-up view of the interface between EgA1 and sEGFR in approximately
the same orientation as in the righthand panel of (A). Only CDR1 (dark blue) and
CDR3 (light blue) participate in the interaction. Key side chains are shown as
sticks and predicted salt-bridge (%4.5 A˚) or hydrogen-bond (%3.5 A˚) in-
teractions are indicated with dashed lines.
(C) View of the 9G8 complex in the same orientation as in (B). CDR1 is identical
and colored as in (B). CDR3 is different (Figure S2) and colored light purple.
See also Figure S3.
Figure 5. Conformational Changes in EgA1 upon Binding to sEGFR
(A) Superposition of free EgA1 (dark gray) and EgA1 bound to sEGFR (white),
with CDR1 and CDR3 in dark and light blue, respectively. The N-terminus of
free EgA1 packs against CDR1 and the hydrophobic core of the Ig fold,
whereas in the bound structure this segment is oriented away from the VHH
and makes (presumed) polar contacts with domain III.
(B and C) Detailed views of the differences in side-chain orientations near the
N-terminus (B) and in CDR2 and CDR3 (C).
See also Figure S4.
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Structural Basis of VHH Domain EGFR Inhibition2008) and, like matuzumab, do not overlap with the EGF binding
region of domain III (Figure 6D). Matuzumab binding is stabilized
by extensive contacts to the domain III b-helix coil 449–463. This
is on the periphery of the EgA1/9G8 epitope, with several main-
chain hydrogen bonds predicted between the VHH N-terminal
region and R27 (upper left hand corners of Figures 4B and 4C).
Simultaneous binding of EgA1/9G8 andmatuzumabwould result
in steric clash of the VHH and Fab domains, consistent with
binding and competition experiments indicating that EgA1 and
9G8 compete with matuzumab for receptor binding (Figure 1;
Roovers et al., 2011). Aside from this small region of overlap,
the matuzumab and EgA1/9G8 epitopes are quite distinct and
share no specificity-determining interactions. The VHH epitopes1220 Structure 21, 1214–1224, July 2, 2013 ª2013 Elsevier Ltd All rigare located farther toward the N-terminal end of domain III and
are farther from the domain III ligand-binding site (Figure 6).
DISCUSSION
Modes of Inhibition of EGFRActivation by VHH Inhibitors
The VHH domains used in this study fall into two categories of
inhibitory antibodies: one typified by cetuximab, the other by
matuzumab. Like cetuximab, 7D12 is a ligand-competitive inhib-
itor. The 7D12 epitope overlaps the ligand-binding site on
domain III of EGFR. In addition, as argued for cetuximab (Li
et al., 2005), bound 7D12 would sterically prevent EGFR from
adopting the extended conformation required for dimerization.
By contrast, EgA1/9G8 do not directly occlude the ligand-bind-
ing site on EGFR. Rather, as argued for matuzumab, inhibition
is achieved by preventing the EGFR extracellular region from
adopting the extended conformation that can dimerize. Like
matuzumab, EgA1/9G8 impose a steric block on this conforma-
tional rearrangement (Schmiedel et al., 2008) (Figure S5). In addi-
tion, EgA1/9G8 appear to stabilize the tethered conformation of
the receptor by binding at the junction between domains II and III
and interacting with key side chains in this region. The domain
II/III junction acts as a hinge in the large-scale domain rearrange-
ment required to take the receptor from the tethered to the
extended (dimerization-competent) conformation, and it is the
site of the most dramatic local differences in backbone confor-
mation between the unliganded and ligand-bound structures
of sEGFR. In tethered sEGFR, the side chain of R310, at thehts reserved
Figure 6. Comparison of the Interactions of EgA1, 9G8, Matuzumab,
and EGF with sEGFR
For each case—(A) EgA1 (blue), (B) 9G8 (violet), (C) matuzumab Fab (teal, PDB
ID 3C09), and (D) EGF (dark red, PDB ID 1IVO)—the righthand image is a
cartoon of just domain III of sEGFR (gray) with bound VHH, Fab, or ligand. The
lefthand image shows a surface representation of domain III in the same
orientation, with the footprint of VHH, Fab, or ligand highlighted.
See also Figure S5 and Table S1.
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Structural Basis of VHH Domain EGFR InhibitionC-terminal end of domain II, projects toward domain III and
makes an electrostatic interaction with the side chain of E376.
This interaction is broken in ligand-bound structures. The altered
main-chain trajectory in the domain II/III interface region results
in the R310 side chain projecting away from domain III. As shown
in Figure 4, EgA1 and 9G8 interact with R310 and E376, effec-
tively locking this region of EGFR into the conformation seen in
tethered, inactive structures. This mode of inhibition may confer
a therapeutic advantage to molecules such as EgA1/9G8,
because binding, and hence inhibition, should not be impacted
by the presence of excess ligand.
Comparison of VHH and Fab Binding to EGFR
Single-domain antibody fragments have certain unique features
that offer modes of interaction with antigens that are underex-
ploited with conventional monoclonal antibodies (MuyldermansStructure 21, 1et al., 2001). Several such VHH-specific binding features are
observed in the interactions of EgA1/9G8 with sEGFR, and
they distinguish the modes of antigen binding by these VHH
domains from those utilized by Fab fragments from cetuximab
and matuzumab.
The single VHH domain of a heavy-chain-only camelid anti-
body functionally replaces the entire Fab fragment of a conven-
tional antibody. To retain binding diversity, VHH domains exhibit
greater variability in the length and accessible conformations of
their three CDRs compared to the six CDRs in a Fab fragment
(Muyldermans et al., 2001). Crystal structures of VHH domains
in complex with more than a dozen different protein antigens
show a range of binding modes that utilize unique features of
VHH domains, and explain how these smaller antigen-recogni-
tion modules can maintain diverse specificity and high affinity.
EgA1/9G8 use a binding mode—with a convex paratope—that
has also been observed for several lysozyme-specific VHH
domains. Like EgA1/9G8, these lysozyme-specific VHH
domains have particularly long CDR3s that extend out from
the VHH framework to recognize a concave epitope at the
enzyme active site (De Genst et al., 2006; Desmyter et al.,
1996). The VHH antigen-recognition domain is uniquely suited
to presentation of highly convex paratopes, and this shape in-
creases the surface available for interaction with the antigen.
The long CDR3 loops of EgA1 and 9G8 contribute to convex
paratopes on these VHH domains that are ideally suited to
bind at the EgA1/9G8 epitope, which is concave because it
lies within a cleft at the domain II/III junction. The larger anti-
gen-binding surface of a Fab is less able to access this epitope
due in part to steric clash of the VL domain. The matuzumab
epitope does partly overlap with that of EgA1/9G8, as expected,
given that the mouse antecedent of matuzumab (mAb425)
competes with EgA1/9G8 for binding to EGFR. However, the
matuzumab epitope is displaced to the domain III side of the
domain II/III junction. Bound matuzumab sterically prevents
the EGFR from adopting the extended conformation observed
in the ligand-bound structures but likely permits EGFR to
access a much greater range of conformations than are acces-
sible to the EgA1/9G8:EGFR complex. EgA1/9G8 lock EGFR in
the tethered, inactive conformation by binding at a key pivot
point. It is also interesting to note that the interaction of matuzu-
mab with EGFR utilizes a binding mode only accessible to a
Fab/antigen interaction. A loop from domain III of sEGFR binds
between the VH and VL domains of the Fab—a convex epitope
interacting with a concave paratope. Other than a substantial
difference in planarity of interfaces involving VHH domains
and Fab fragments, the general characteristics of the interfaces
formed by the two classes of antibody are very similar (Table
S1), as was reported in a study of VHH and Fab fragments bind-
ing to lysozyme (De Genst et al., 2006).
By contrast to EgA1/9G8, 7D12 interacts with a relatively flat
epitope, using only CDR1 and CDR3 in a manner reminiscent
of the binding of several VHH domains to ribonuclease A (Koide
et al., 2007). CDR3 folds back against the framework of the VHH
domain and is stabilized by van der Waals contacts and
hydrogen bonds (although not by a disulfide bond, as often
occurs in camel HCAbs; Nguyen et al., 2001). This creates a
stable flat paratope that interacts with a region close to, although
not entirely overlapping, the cetuximab epitope.214–1224, July 2, 2013 ª2013 Elsevier Ltd All rights reserved 1221
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Therapeutic Agents
The structures presented here illustrate two important features
of VHH domains that make them valuable additions to the drug
discovery toolkit. For EgA1/9G8, the unique structure of the
VHH domain allows recognition of an epitope that is inaccessible
to a conventional mAb, generating an inhibitor with a new mode
of EGFR inhibition. The structure of 7D12 bound to domain III of
EGFR reveals how this smaller and readily engineered binding
unit can mimic inhibitory features of the intact monoclonal anti-
body drug cetuximab. Multimerization of 7D12 with other VHH
domains generates a potent EGFR inhibitor (Roovers et al.,
2011). 7D12 is thus a cassette that can be used to combine
cetuximab-like inhibition with modules of synergistic and/or
complementary inhibitory properties. Availability of a repertoire
of similarly well-characterized inhibitory VHH domains could
facilitate the generation of multivalent/multispecific drugs that
can ultimately be ‘‘personalized’’ for optimal effect against a
patient’s tumor.
EXPERIMENTAL PROCEDURES
Protein Production
sEGFR (amino acids [aa] 1–618 of mature EGFR), sEGFR501 (aa 1–501), and
sEGFRd3 (aa 1–4 followed by aa 311–514) were produced and purified as
described (Ferguson et al., 2000; Li et al., 2005). To generate sEGFRvIII,
codons 6–273 of wild-type sEGFR were replaced with a single glycine codon
using standard molecular biology methods, sEGFRvIII expressed and purified
as for sEGFR. DNA coding VHH fragments 7D12, EgA1, and 9G8 was cloned
into pET-22b (EMD). For crystallization, proteins included a C-terminal hexa-
histidine (H6) tag (VHH-H6), whereas for binding experiments, a C-terminal
E. coli BirA biotinylation sequence (GLNDIFEAQKIEWH) (Beckett et al.,
1999) followed by an H6 tag (VHH-AVI) was included. An upstream pelB leader
sequence directed periplasmic expression. VHHs were overexpressed in Luria
Broth by lactose autoinduction (Studier, 2005). VHHs were extracted by
freeze/thaw in PBS (25 mM Na2HPO4/NaH2PO4, 150 mM NaCl, and 10%
glycerol [pH 8.0]). Lysates were applied to Ni-NTA resin (Qiagen) and eluted
with an imidazole gradient. Fractions containing VHHs were concentrated
and further purified by size-exclusion chromatography (Superose 12, GE
Healthcare) using a buffer of 25mMHEPES and 150mMNaCl (pH 8.0). sEGFR
and VHH variants incorporating site-directed alterations were generated by
standard PCR methods. VHH:sEGFR complexes for crystallization were puri-
fied by size-exclusion chromatography. mAb425 was a generous gift from
Prof. Ulrich Rodeck (Jefferson University). The Fab fragments were prepared
by papain cleavage and protein A purification using the Pierce Fab Preparation
Kit (Thermo Scientific) and used without further purification. EGF was pur-
chased from Chemicon.
Crystallization and Data Collection
Crystals were grown using the hanging-drop vapor-diffusion method at 20C.
In each case, protein was mixed with crystallization buffer and equilibrated
against a reservoir of this same buffer. The following conditions were used:
(1) EgA1 alone, 0.5 ml of 18 mg/ml EgA1 plus 1.0 ml of 30% polyethylene glycol
(PEG) 3350, 0.2 M (NH4)2SO4, 0.1 MMES buffer (pH 6.0); (2) 7D12:sEGFRd3 at
pH 6, 0.5 ml of 10 mg/ml complex plus 0.5 ml 22.5% PEG3350, 50 mMKI, 0.1 M
MES buffer (pH 6.0); (3) 7D12:sEGFRd3 at pH 3, 1.0 ml of 10 mg/ml complex
plus 1.5 ml of 22.5% PEG3350, 0.1 M sodium citrate (pH 3.5); (4) EgA1:
FabC225:sEGFR, 0.5 ml of 11 mg/ml complex plus 0.5 ml of 17.5%
PEG3350, 1.5 M NaCl, 5% glycerol, 0.1 M MES buffer (pH 6.5); (5)
9G8:FabC225:sEGFR, 0.5 ml of 7 mg/ml protein and 2.5 ml of 10% PEG3350,
and 0.1 M HEPES [pH 7.0]). All crystals were flash frozen in liquid nitrogen
from cryostabilizers. EgA1 was flash frozen directly from the crystallization
drop. Crystals from conditions 2–5 were transferred to crystallization buffer
supplemented with 12.5% glycerol (condition 2), 5% ethylene glycol (condition
3), 2.5%PEG3350 and 7.5%glycerol (condition 4), and 5%PEG3350 and 15%1222 Structure 21, 1214–1224, July 2, 2013 ª2013 Elsevier Ltd All rigethylene glycol (condition 5). X-ray diffraction data were collected at GM/CA@
APS beamline ID 23-B (EgA1, 7D12:sEGFRd3, and 9G8:FabC225:sEGFR) and
at CHESS beamline F1 (EgA1:FabC225:sEGFR).
Structure Determination and Refinement
Data were processed with HKL-2000 (Otwinowski and Minor, 1997). All struc-
tures were solved by molecular replacement (MR) in the program PHASER
(McCoy et al., 2007). The framework region of a hapten-binding VHH (PDB
ID 1I3V) was used as the search model for the structure of EgA1 alone.
EGFR domain III from PDB ID 3B2U (chain A) and the framework region of
EgA1 were used as independent search models to solve 7D12:sEGFRd3 at
pH 6.0; the resulting complex served as the search model to identify the six
copies of 7D12:sEGFRd3 in the pH 3.5 data. For the EgA1:FabC225:sEGFR
complex, EgA1, the C225 Fv region, the C225 CH2/CL region, EGFR domains
I and II, and EGFR domains III and IV (PDB ID 1YY9) were used as independent
search models. The EgA1:FabC225:sEGFR structure was used as the search
model to solve the 9G8:FabC225:sEGFR complex. Protein models were built
in COOT (Emsley and Cowtan, 2004), and refined using REFMAC (CCP4,
1994), CNS (Bru¨nger et al., 1998) and PHENIX (Adams et al., 2010). The pres-
ence of an iodide ion in the pH 6.0 7D12:sEGFRd3 model was confirmed by
inspection of an anomalous difference map. In the EgA1/9G8 complexes,
FabC225 and EGFR amino acids 208–605 are well ordered, as is most of the
VHH. EGFR domain I, the N-terminal portion of domain II, and the distal portion
of the VHH are poorly ordered. The dihedral angles in domain I were restrained
to those in PDB ID 1YY9. Data collection and refinement statistics are summa-
rized in Table 2.
Structure Analysis
Shape complementarity values were determined by the Sc module in CCP4
(CCP4, 1994), excluding solvent molecules. Interactions between chains
were identified by NCONT in CCP4, using a distance cutoff of 3.5 A˚ for
hydrogen bonds and van der Waals contacts and a cutoff of 4.5 A˚ for electro-
static interactions. Average excluded surface areas were calculated by
CONTACT in CCP4. The fraction of buried hydrophobic surface area was
determined by dividing the surface area of buried carbon atoms by the total
buried surface area. Structural alignments and rmsd values were generated
within the programs PYMOL or COOT, and reflect main-chain atoms only.
Analytical Ultracentrifugation
Sedimentation velocity analytical ultracentrifugation experiments were con-
ducted in a Beckman Optima XL-A instrument in an An-Ti 60 rotor at 20C,
at 35,000–50,000 rpm in 10 mM HEPES and 150 mM NaCl (pH 8.0). Sample
absorbance was monitored at 280 nm. Buffer density, buffer viscosity, and
protein partial specific volume were estimated in the program SEDNTERP
(Philo et al., 1996). Size-distribution c(S) analysis was performed with the pro-
gram SEDFIT (Schuck, 2000). Only c(S) fits producing low residuals with no
systematic error are reported.
Surface Plasmon Resonance Studies
SPR binding experiments were performed with a Biacore 3000 instrument at
25C. Immobilized species were diluted to 50 mg/ml (Fabs), 100 mg/ml
(VHHs), or 200 mg/ml (EGF) in acidic buffer (10 mM sodium acetate at pH 4.0
for Fab425 and EGF, pH 5.0 for VHHs, and pH 5.5 for FabC225) and were
amine coupled to activated CM5 sensor chips at 5 ml/min for 5–10min. Binding
of sEGFR to these surfaces was determined as described (Ferguson et al.,
2000; Li et al., 2005). VHH-AVI constructs were exogenously biotinylated by
BirA as described (Abbott and Beckett, 1993; Beckett et al., 1999) and immo-
bilized to streptavidin-coated SA sensor chips. Surfaces were regenerated
between data points with 5 ml of 1 M NaCl at low pH (2.5–5.5) to remove
residual sEGFR. Multiple cycles of regeneration did not impair sEGFR binding.
Data were analyzed using Prism 4 (GraphPad Software).
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